Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026GlobeNewsWire · 4 days ago
Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination SyndromeGlobeNewsWire · Oct 14, 2026
Invivyd’s VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated ApprovalDefense World · Oct 5, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 5, 2026
Invivyd's VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated ApprovalMarketBeat · Oct 4, 2026
Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 AntibodyBenzinga · Sep 29, 2026Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.11 | -$0.14 | Miss |
| May 14, 2026 | -$0.08 | -$0.13 | Miss |
| Mar 5, 2026 | -$0.06 | $0.02 | Beat |
| Nov 6, 2025 | -$0.05 | -$0.06 | Miss |
| Aug 14, 2025 | -$0.04 | -$0.12 | Miss |
| May 15, 2025 | -$0.04 | -$0.14 | Miss |